Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 101 results for melanoma

  1. AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)

    NICE has developed a medtech innovation briefing (MIB) on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas .

  2. Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (IPG155)

    Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions). This involves applying (or sometimes injecting) a photosensitising agent and using light to activate it, destroying the tumour cells.

  3. Suspected cancer: recognition and referral (NG12)

    This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

  4. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

  5. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

    This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.

  6. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development [GID-TAG509] Expected publication date: 28 September 2016

  7. Histological margins: What is the optimal histological excision margin in stage 0 melanoma?

    Histological margins: What is the optimal histological excision margin in stage 0 melanoma? Any explanatory notes(if applicable) For a...

  8. Effectiveness of localised treatments: What is the effectiveness of localised treatment for people with stages III and IV melanoma?

    effectiveness of localised treatment for people with stages III and IV melanoma? Any explanatory notes(if applicable) For a short...

  9. Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment planning for people with melanoma?

    be used for risk stratification and treatment planning for people with melanoma? Any explanatory notes(if applicable) For a short...

  10. Survivorship: What are the experiences of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease journey?

    are the experiences of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease...

  11. Surveillance strategies: How frequently should surveillance imaging be conducted, and which imaging modality should be used for people with stage IIB to IIIC melanoma?

    which imaging modality should be used for people with stage IIB to IIIC melanoma? Any explanatory notes(if applicable) For a short...

  12. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (IPG691)

    Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.

  13. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over (NG36)

    This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 and over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. It aims to reduce variation in practice and improve survival.

  14. Technology appraisal and highly specialised technologies appeals

    Technology appraisal and Highly specialised technologies appeals